Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anthony Elias

Concepts (664)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
108
2024
2264
6.060
 Why?
Antineoplastic Combined Chemotherapy Protocols
96
2025
1697
4.110
 Why?
Sarcoma
33
2025
184
3.870
 Why?
Receptors, Estrogen
22
2021
435
2.320
 Why?
Triple Negative Breast Neoplasms
14
2024
205
2.250
 Why?
Receptor, ErbB-2
22
2024
339
2.030
 Why?
Hematopoietic Stem Cell Transplantation
36
2011
623
1.980
 Why?
Carcinoma, Small Cell
19
2003
172
1.710
 Why?
Soft Tissue Neoplasms
14
2022
113
1.580
 Why?
Carcinoma, Ductal, Breast
7
2018
83
1.490
 Why?
Neoadjuvant Therapy
17
2024
420
1.320
 Why?
Antineoplastic Agents
31
2023
2126
1.230
 Why?
Neoplasm Recurrence, Local
20
2022
1062
1.150
 Why?
Neoplasm Staging
35
2024
1369
1.060
 Why?
Receptors, Progesterone
13
2020
349
1.050
 Why?
Lung Neoplasms
38
2003
2508
1.020
 Why?
Combined Modality Therapy
52
2024
1218
1.010
 Why?
Doxorubicin
24
2025
338
1.010
 Why?
Biomarkers, Tumor
17
2022
1250
0.980
 Why?
Paclitaxel
14
2024
239
0.910
 Why?
CTLA-4 Antigen
1
2025
97
0.910
 Why?
Mastectomy
9
2018
138
0.900
 Why?
Bone Marrow Transplantation
27
1998
287
0.900
 Why?
Bone Neoplasms
7
2025
242
0.850
 Why?
Antibodies, Monoclonal, Humanized
10
2025
797
0.830
 Why?
Antineoplastic Agents, Alkylating
5
2018
70
0.750
 Why?
Female
168
2025
73054
0.740
 Why?
Receptors, Androgen
7
2018
152
0.720
 Why?
Disease-Free Survival
24
2023
671
0.710
 Why?
Humans
226
2025
136960
0.700
 Why?
Middle Aged
112
2025
33242
0.680
 Why?
Antineoplastic Agents, Hormonal
10
2018
162
0.670
 Why?
Maytansine
3
2021
16
0.650
 Why?
Liposarcoma
4
2023
27
0.650
 Why?
Adult
114
2025
37690
0.600
 Why?
Neoplasm Metastasis
23
2024
656
0.600
 Why?
Chemotherapy, Adjuvant
23
2023
388
0.590
 Why?
Dioxoles
2
2015
9
0.560
 Why?
Tetrahydroisoquinolines
2
2015
8
0.560
 Why?
Cyclophosphamide
31
2024
242
0.560
 Why?
Aged
65
2025
23838
0.520
 Why?
Ifosfamide
19
1998
37
0.510
 Why?
Androgen Receptor Antagonists
6
2021
35
0.510
 Why?
Phenylthiohydantoin
5
2017
42
0.510
 Why?
Dasatinib
1
2016
54
0.500
 Why?
Trastuzumab
10
2024
96
0.490
 Why?
Neoplasms, Hormone-Dependent
3
2012
38
0.480
 Why?
Treatment Outcome
43
2024
10715
0.470
 Why?
Drug Administration Schedule
24
2018
749
0.450
 Why?
Estrogen Receptor alpha
5
2021
144
0.450
 Why?
Carboplatin
21
2016
142
0.450
 Why?
Granulocyte Colony-Stimulating Factor
11
2002
82
0.440
 Why?
Carcinoma, Non-Small-Cell Lung
17
2001
1068
0.430
 Why?
Clinical Trials as Topic
19
2018
1015
0.420
 Why?
Estrogens
6
2018
366
0.400
 Why?
Dacarbazine
9
2018
93
0.390
 Why?
Survival Rate
19
2021
1927
0.370
 Why?
Tamoxifen
9
2018
202
0.360
 Why?
Neoplasms
20
2009
2703
0.360
 Why?
Survival Analysis
23
2010
1293
0.360
 Why?
Prognosis
22
2021
3979
0.350
 Why?
Venous Thromboembolism
3
2020
315
0.350
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2013
972
0.350
 Why?
Pyrimidines
3
2020
469
0.340
 Why?
Programmed Cell Death 1 Receptor
2
2025
249
0.340
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2022
56
0.330
 Why?
Antibodies, Monoclonal
9
2024
1414
0.330
 Why?
Neoplasms, Second Primary
3
2022
117
0.330
 Why?
Dose-Response Relationship, Drug
17
2017
2007
0.330
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
8
1999
152
0.330
 Why?
Taxoids
7
2023
101
0.320
 Why?
Remission Induction
16
2002
285
0.320
 Why?
Breast Neoplasms, Male
3
2018
29
0.320
 Why?
Drug Resistance, Neoplasm
7
2017
792
0.310
 Why?
Gene Expression Regulation, Neoplastic
11
2018
1388
0.300
 Why?
Neoplastic Cells, Circulating
2
2020
79
0.290
 Why?
Mesna
12
1998
16
0.280
 Why?
Sarcoma, Ewing
3
2022
97
0.270
 Why?
Leiomyosarcoma
2
2018
27
0.260
 Why?
Cisplatin
14
2000
320
0.260
 Why?
Immunoconjugates
3
2024
114
0.260
 Why?
Sternum
1
2006
25
0.250
 Why?
Immunohistochemistry
5
2016
1726
0.250
 Why?
Tumor Microenvironment
4
2024
679
0.250
 Why?
Mastectomy, Segmental
2
2009
93
0.240
 Why?
Pyridines
2
2025
498
0.240
 Why?
Chondrosarcoma
1
2025
15
0.240
 Why?
Peripheral Blood Stem Cell Transplantation
2
2002
23
0.230
 Why?
Carcinoma, Ductal
1
2005
11
0.230
 Why?
Male
66
2025
67419
0.230
 Why?
Transplantation, Autologous
19
2002
240
0.230
 Why?
Melphalan
10
2002
35
0.230
 Why?
Isocitrate Dehydrogenase
1
2025
57
0.230
 Why?
Protein Kinase Inhibitors
4
2019
903
0.230
 Why?
Cell Adhesion Molecules
2
2021
176
0.220
 Why?
Lymph Nodes
1
2007
487
0.220
 Why?
Carcinoma
2
2008
228
0.220
 Why?
Glycine
1
2025
175
0.220
 Why?
Risk Reduction Behavior
2
2016
218
0.220
 Why?
Drug Evaluation
19
1998
79
0.210
 Why?
Adjuvants, Immunologic
3
2022
229
0.210
 Why?
Deoxycytidine
4
2020
190
0.210
 Why?
Ribonuclease III
2
2016
40
0.210
 Why?
Ovarian Neoplasms
3
2022
568
0.210
 Why?
Hodgkin Disease
4
2016
137
0.210
 Why?
Survivors
3
2016
499
0.210
 Why?
Thiotepa
13
2002
20
0.200
 Why?
Alkylating Agents
3
2000
24
0.200
 Why?
Triazoles
2
2022
150
0.200
 Why?
DEAD-box RNA Helicases
2
2016
75
0.200
 Why?
Aged, 80 and over
14
2021
7596
0.200
 Why?
Weight Loss
4
2016
787
0.200
 Why?
Behavior Therapy
2
2016
269
0.200
 Why?
Gene Expression Profiling
6
2017
1751
0.190
 Why?
Disease Management
5
2020
610
0.190
 Why?
Employment
1
2024
179
0.190
 Why?
Medical Oncology
5
2024
297
0.190
 Why?
Overweight
3
2016
576
0.190
 Why?
Mutation
4
2025
3978
0.190
 Why?
Obesity
4
2018
3028
0.190
 Why?
Salvage Therapy
6
2010
138
0.190
 Why?
Circulating Tumor DNA
1
2022
31
0.190
 Why?
Hydrazines
1
2022
37
0.190
 Why?
Carcinoma in Situ
2
2012
48
0.180
 Why?
Etoposide
10
2001
158
0.180
 Why?
Referral and Consultation
1
2007
780
0.180
 Why?
Hematologic Diseases
6
2008
64
0.180
 Why?
Tumor Cells, Cultured
9
2020
948
0.180
 Why?
Emergency Medicine
1
2024
232
0.180
 Why?
Liposarcoma, Myxoid
1
2021
10
0.180
 Why?
Sarcoma, Synovial
1
2021
21
0.180
 Why?
Recombinant Fusion Proteins
1
2024
661
0.170
 Why?
Aromatase Inhibitors
4
2021
57
0.170
 Why?
Endpoint Determination
1
2021
76
0.170
 Why?
Sentinel Lymph Node Biopsy
3
2017
114
0.170
 Why?
Indazoles
1
2020
67
0.170
 Why?
Leukocytes, Mononuclear
3
2020
555
0.160
 Why?
Time Factors
12
2020
6786
0.160
 Why?
Hematopoietic Stem Cells
5
1996
407
0.160
 Why?
Cancer Care Facilities
1
2020
43
0.160
 Why?
Cell Separation
3
2017
312
0.160
 Why?
Diphosphonates
1
2020
67
0.160
 Why?
Pyrroles
2
2013
213
0.160
 Why?
Bone Marrow
8
2000
298
0.160
 Why?
Diet
3
2018
1279
0.160
 Why?
Nuclear Medicine
1
2019
9
0.150
 Why?
Antigens, Neoplasm
4
2021
318
0.150
 Why?
Hematology
1
2019
19
0.150
 Why?
Proportional Hazards Models
6
2020
1252
0.150
 Why?
Cell Line, Tumor
9
2017
3410
0.150
 Why?
MCF-7 Cells
5
2017
124
0.150
 Why?
CA-125 Antigen
2
2013
14
0.150
 Why?
Fluorouracil
7
2013
218
0.150
 Why?
Epithelial-Mesenchymal Transition
1
2020
211
0.150
 Why?
Thromboembolism
1
2019
120
0.140
 Why?
Pulmonary Medicine
1
2019
81
0.140
 Why?
Benzamides
5
2017
214
0.140
 Why?
Nitriles
5
2017
173
0.140
 Why?
Bayes Theorem
4
2024
409
0.140
 Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2018
53
0.140
 Why?
Cyclin-Dependent Kinase 4
1
2018
47
0.140
 Why?
Cyclin-Dependent Kinase 6
1
2018
42
0.140
 Why?
Infusions, Intravenous
10
2020
390
0.140
 Why?
Cell Cycle
1
2021
600
0.140
 Why?
Research Design
3
2021
1115
0.140
 Why?
Tissue Inhibitor of Metalloproteinase-3
1
2017
9
0.140
 Why?
Kaplan-Meier Estimate
6
2018
872
0.140
 Why?
Indoles
2
2013
408
0.140
 Why?
Anesthesiology
1
2019
86
0.140
 Why?
Schwann Cells
1
2017
35
0.140
 Why?
Tetrahydronaphthalenes
1
2017
30
0.140
 Why?
Sciatic Nerve
1
2017
58
0.130
 Why?
Microbubbles
1
2017
47
0.130
 Why?
Valine
1
2017
76
0.130
 Why?
Vaccines
1
2022
400
0.130
 Why?
Betacoronavirus
1
2020
269
0.130
 Why?
Societies, Medical
2
2019
809
0.130
 Why?
Venous Thrombosis
1
2019
186
0.130
 Why?
Camptothecin
3
2024
115
0.130
 Why?
Lymph Node Excision
3
2015
171
0.130
 Why?
Amyloid Precursor Protein Secretases
1
2017
81
0.130
 Why?
Axilla
3
2017
47
0.130
 Why?
Sulfonamides
1
2020
508
0.130
 Why?
Immunotherapy
2
2018
637
0.130
 Why?
Androgen Antagonists
2
2015
83
0.130
 Why?
Cancer-Associated Fibroblasts
1
2016
19
0.130
 Why?
Gonadal Steroid Hormones
1
2018
139
0.130
 Why?
Internship and Residency
2
2024
1159
0.130
 Why?
Hematopoietic Cell Growth Factors
2
1995
4
0.130
 Why?
Ultrasonography, Mammary
1
2016
13
0.120
 Why?
Neoplasms, Radiation-Induced
1
2016
91
0.120
 Why?
Neoplasms, Germ Cell and Embryonal
2
1995
77
0.120
 Why?
Thiazoles
1
2016
125
0.120
 Why?
Follow-Up Studies
6
2025
5072
0.120
 Why?
Lymphatic Metastasis
3
2017
341
0.120
 Why?
Antibody Specificity
1
2016
187
0.120
 Why?
Tumor Suppressor Protein p53
2
2023
525
0.120
 Why?
Neoplasm Invasiveness
3
2016
514
0.120
 Why?
Myelin Sheath
1
2017
167
0.120
 Why?
Ambulatory Care
1
2020
558
0.120
 Why?
Maximum Tolerated Dose
1
2016
199
0.120
 Why?
Antibiotics, Antineoplastic
1
2016
124
0.120
 Why?
Neoplastic Stem Cells
2
2017
399
0.120
 Why?
Quinolines
1
2016
153
0.120
 Why?
Benzimidazoles
1
2016
170
0.120
 Why?
Pneumonia, Viral
1
2020
368
0.110
 Why?
Pyrazoles
1
2018
420
0.110
 Why?
Coronavirus Infections
1
2020
366
0.110
 Why?
Recurrence
5
2020
1057
0.110
 Why?
Drug Therapy, Combination
4
2014
1014
0.110
 Why?
Animals
17
2021
36934
0.110
 Why?
Mammography
1
2016
158
0.110
 Why?
Disease Progression
7
2018
2707
0.110
 Why?
Radiotherapy, Adjuvant
5
2016
214
0.110
 Why?
Homeodomain Proteins
2
2018
506
0.110
 Why?
Administration, Oral
4
2020
782
0.110
 Why?
Antibodies
1
2016
408
0.110
 Why?
Brain Edema
1
2014
60
0.110
 Why?
Hepatic Veno-Occlusive Disease
3
2002
14
0.110
 Why?
Young Adult
10
2025
13202
0.110
 Why?
Radiotherapy Dosage
3
1999
264
0.110
 Why?
TOR Serine-Threonine Kinases
1
2017
410
0.110
 Why?
Exercise
2
2015
2074
0.100
 Why?
Vascular Neoplasms
1
2013
19
0.100
 Why?
Comorbidity
5
2017
1613
0.100
 Why?
Clinical Trials, Phase I as Topic
3
2024
50
0.100
 Why?
Radiotherapy
3
2015
200
0.100
 Why?
Testicular Neoplasms
1
1995
111
0.100
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2022
116
0.100
 Why?
Epigenesis, Genetic
2
2018
651
0.100
 Why?
Keratins
2
2017
171
0.100
 Why?
Mice
12
2021
17757
0.100
 Why?
Cellular Reprogramming
1
2014
98
0.100
 Why?
Bridged-Ring Compounds
3
2020
14
0.100
 Why?
Mercaptoethanol
2
1990
11
0.100
 Why?
Adenocarcinoma
6
2015
944
0.100
 Why?
Apoptosis
6
2023
2547
0.100
 Why?
Patient Selection
4
2016
688
0.100
 Why?
Cell Proliferation
6
2017
2465
0.100
 Why?
Gallium Radioisotopes
1
1992
14
0.100
 Why?
Bone Marrow Cells
4
2000
316
0.100
 Why?
Chromatin
1
2016
516
0.100
 Why?
Carmustine
10
2001
50
0.090
 Why?
Protein-Tyrosine Kinases
2
2022
424
0.090
 Why?
Adolescent
23
2025
21463
0.090
 Why?
Anthracyclines
3
2023
42
0.090
 Why?
Lymphoma, Non-Hodgkin
3
2001
85
0.090
 Why?
Methotrexate
4
2002
250
0.090
 Why?
Brain Neoplasms
5
2014
1217
0.090
 Why?
Retrospective Studies
12
2023
15619
0.090
 Why?
Weight Reduction Programs
1
2012
117
0.090
 Why?
Neoplasm, Residual
2
2022
133
0.090
 Why?
RNA, Catalytic
1
2012
188
0.090
 Why?
Radiosurgery
1
2014
344
0.090
 Why?
Risk Assessment
3
2020
3462
0.090
 Why?
Polydeoxyribonucleotides
2
2002
14
0.090
 Why?
Aorta
1
2013
414
0.090
 Why?
Age Factors
5
2019
3263
0.080
 Why?
Neutropenia
5
2013
151
0.080
 Why?
Carcinoma, Lobular
1
2011
49
0.080
 Why?
Neoplasm Grading
3
2017
303
0.080
 Why?
Multivariate Analysis
4
2013
1480
0.080
 Why?
Leukapheresis
4
2001
24
0.080
 Why?
Keratin-5
1
2010
49
0.080
 Why?
Angiogenesis Inhibitors
1
2012
228
0.080
 Why?
Liver Neoplasms
3
2015
801
0.080
 Why?
Biopsy
3
2018
1086
0.080
 Why?
Molecular Targeted Therapy
3
2018
405
0.080
 Why?
Practice Patterns, Physicians'
1
2019
1292
0.080
 Why?
Peptide Mapping
1
2010
64
0.080
 Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
111
0.080
 Why?
Databases, Protein
1
2010
86
0.080
 Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
143
0.080
 Why?
Benzenesulfonates
1
2009
22
0.080
 Why?
Postmenopause
2
2017
369
0.080
 Why?
Urinary Tract
1
1990
49
0.080
 Why?
CD146 Antigen
2
2021
42
0.080
 Why?
BRCA2 Protein
1
2009
63
0.080
 Why?
Health Facilities
1
2009
84
0.080
 Why?
Pregnancy Complications, Neoplastic
1
2009
53
0.080
 Why?
Thrombophilia
1
2009
84
0.070
 Why?
Observer Variation
1
2010
341
0.070
 Why?
Patient Care
1
2009
111
0.070
 Why?
Risk Factors
8
2020
10367
0.070
 Why?
United States
9
2023
14894
0.070
 Why?
Perimenopause
1
2008
64
0.070
 Why?
Mice, Nude
3
2017
695
0.070
 Why?
Fibrinolytic Agents
2
2002
270
0.070
 Why?
Bone Marrow Diseases
4
2000
20
0.070
 Why?
In Situ Hybridization
2
2010
317
0.070
 Why?
Fatigue
3
2018
336
0.070
 Why?
In Situ Hybridization, Fluorescence
1
2008
311
0.070
 Why?
Randomized Controlled Trials as Topic
6
2000
1455
0.070
 Why?
Xenograft Model Antitumor Assays
3
2017
869
0.070
 Why?
Blotting, Western
1
2010
1218
0.070
 Why?
Pneumonectomy
3
1997
148
0.060
 Why?
Sputum
1
1988
304
0.060
 Why?
Reproducibility of Results
2
2016
3247
0.060
 Why?
Quality of Life
2
2015
2895
0.060
 Why?
Proto-Oncogene Proteins c-akt
2
2019
437
0.060
 Why?
Clinical Decision-Making
2
2020
324
0.060
 Why?
Neoplasm Proteins
2
2007
430
0.060
 Why?
Life Tables
2
2002
19
0.060
 Why?
Anilides
2
2016
71
0.060
 Why?
New Jersey
1
2024
14
0.060
 Why?
Positron-Emission Tomography
1
2006
298
0.060
 Why?
Colony-Stimulating Factors
3
1988
37
0.060
 Why?
Predictive Value of Tests
2
2016
2015
0.060
 Why?
Enzyme Inhibitors
1
2008
840
0.050
 Why?
Receptor, TIE-2
1
2024
12
0.050
 Why?
Anticoagulants
2
2019
656
0.050
 Why?
Granulocytes
4
1995
84
0.050
 Why?
New York
1
2024
123
0.050
 Why?
Oligonucleotide Array Sequence Analysis
3
2012
757
0.050
 Why?
Genes, Neoplasm
1
2004
22
0.050
 Why?
Ricin
2
1997
8
0.050
 Why?
Growth Substances
3
1988
148
0.050
 Why?
MicroRNAs
1
2010
682
0.050
 Why?
Forecasting
3
2000
388
0.050
 Why?
Patient Care Planning
1
2005
156
0.050
 Why?
Magnetic Resonance Imaging
1
2016
3541
0.050
 Why?
Thrombocytopenia
3
2013
198
0.050
 Why?
Up-Regulation
2
2017
841
0.050
 Why?
Mammaplasty
2
2016
107
0.050
 Why?
Activating Transcription Factor 4
1
2023
20
0.050
 Why?
Signal Transduction
5
2018
5058
0.050
 Why?
Proteasome Inhibitors
1
2023
43
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
65
0.050
 Why?
G(M2) Ganglioside
1
2022
1
0.050
 Why?
Injection Site Reaction
1
2022
3
0.050
 Why?
Proteomics
1
2010
1110
0.050
 Why?
Cyclin E
1
2022
25
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2000
97
0.050
 Why?
Transcriptome
2
2023
968
0.050
 Why?
Treatment Failure
2
2001
340
0.050
 Why?
Luminescent Measurements
1
2003
73
0.050
 Why?
France
2
2019
33
0.050
 Why?
Oncogene Proteins
1
2022
58
0.050
 Why?
Ribose
1
2022
23
0.050
 Why?
Blood Transfusion, Autologous
2
1993
18
0.050
 Why?
Carbolines
1
2022
32
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
155
0.050
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2022
20
0.050
 Why?
Adenosine Diphosphate
1
2022
80
0.050
 Why?
Career Choice
1
2024
226
0.050
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2022
94
0.050
 Why?
Actuarial Analysis
2
1993
23
0.050
 Why?
Oncogenes
1
2022
116
0.050
 Why?
Tomography, X-Ray Computed
2
2015
2677
0.050
 Why?
Gene Expression
2
2020
1482
0.040
 Why?
Colony-Forming Units Assay
4
1996
96
0.040
 Why?
Cell Division
2
2001
788
0.040
 Why?
Carcinoembryonic Antigen
1
2001
41
0.040
 Why?
Phthalazines
1
2021
44
0.040
 Why?
Fellowships and Scholarships
1
2024
300
0.040
 Why?
Prospective Studies
5
2022
7511
0.040
 Why?
Transplantation Immunology
1
2000
32
0.040
 Why?
Clodronic Acid
1
2020
18
0.040
 Why?
Longitudinal Studies
2
2012
2843
0.040
 Why?
Extracellular Matrix
1
2024
533
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
367
0.040
 Why?
Progesterone
1
2002
255
0.040
 Why?
Ligands
1
2022
662
0.040
 Why?
Estradiol
2
2016
521
0.040
 Why?
Topoisomerase I Inhibitors
1
1999
17
0.040
 Why?
Thoracotomy
2
1997
75
0.040
 Why?
Polymerase Chain Reaction
1
2003
1049
0.040
 Why?
Hematopoietic Stem Cell Mobilization
1
1999
23
0.040
 Why?
Leucovorin
2
1997
86
0.040
 Why?
Bone Density Conservation Agents
1
2020
80
0.040
 Why?
Dendritic Cells
2
2000
484
0.040
 Why?
Mechlorethamine
1
2000
59
0.040
 Why?
Myelodysplastic Syndromes
1
2001
136
0.040
 Why?
Drug Resistance
1
1999
144
0.040
 Why?
Neoplasms, Experimental
1
2000
175
0.040
 Why?
Heterocyclic Compounds, 3-Ring
1
2019
32
0.040
 Why?
Receptors, Steroid
1
2019
46
0.040
 Why?
Piperazines
1
2021
345
0.040
 Why?
Cluster Analysis
2
2012
510
0.040
 Why?
Cell Cycle Proteins
1
2022
616
0.040
 Why?
Child
8
2022
21775
0.040
 Why?
Etanidazole
1
1998
1
0.040
 Why?
Enterocolitis, Pseudomembranous
1
1998
28
0.040
 Why?
Leukemia
1
2001
240
0.040
 Why?
Expectorants
1
1998
23
0.040
 Why?
Loss of Function Mutation
1
2018
46
0.040
 Why?
Aurora Kinase A
1
2018
56
0.040
 Why?
Cross-Over Studies
1
2020
545
0.040
 Why?
Nervous System
2
1997
66
0.040
 Why?
Statistics, Nonparametric
1
1999
425
0.040
 Why?
Mediastinum
1
1998
21
0.040
 Why?
Retreatment
1
2018
71
0.040
 Why?
Disease Susceptibility
1
2020
346
0.040
 Why?
Nausea
1
2018
110
0.040
 Why?
Epithelial Cell Adhesion Molecule
1
2017
11
0.030
 Why?
Myelin Basic Protein
1
2017
47
0.030
 Why?
Administration, Intravenous
1
2018
152
0.030
 Why?
ADAM17 Protein
1
2017
35
0.030
 Why?
Extremities
2
1989
129
0.030
 Why?
Bromodeoxyuridine
1
2017
78
0.030
 Why?
Watchful Waiting
1
2018
77
0.030
 Why?
Breast
1
2018
154
0.030
 Why?
SEER Program
1
2018
226
0.030
 Why?
Ganglia, Spinal
1
2017
78
0.030
 Why?
Diarrhea
1
2018
183
0.030
 Why?
Cell Hypoxia
1
1998
226
0.030
 Why?
Double-Blind Method
1
2022
1905
0.030
 Why?
Medicare
1
2023
781
0.030
 Why?
Thorax
1
1997
45
0.030
 Why?
Random Allocation
2
1988
352
0.030
 Why?
Everolimus
1
2017
88
0.030
 Why?
Phosphoramide Mustards
1
2016
3
0.030
 Why?
Coculture Techniques
1
2017
240
0.030
 Why?
Heterografts
1
2017
135
0.030
 Why?
Cohort Studies
4
2001
5679
0.030
 Why?
Cyclohexanes
1
2016
21
0.030
 Why?
Immunotoxins
1
1997
56
0.030
 Why?
Cells, Cultured
2
2017
4133
0.030
 Why?
Cytochrome P-450 CYP3A
1
2017
87
0.030
 Why?
Cell Survival
1
2000
1123
0.030
 Why?
Placebos
1
2016
195
0.030
 Why?
Fluorescence Resonance Energy Transfer
1
2017
173
0.030
 Why?
Ascorbic Acid
1
2017
178
0.030
 Why?
Lymphoma, Large B-Cell, Diffuse
1
1998
121
0.030
 Why?
Gene Knockdown Techniques
1
2017
330
0.030
 Why?
Carcinogenesis
1
2018
218
0.030
 Why?
Injections, Intravenous
2
1993
194
0.030
 Why?
Antineoplastic Agents, Immunological
1
2018
189
0.030
 Why?
Fertility Preservation
1
2016
49
0.030
 Why?
Blood Specimen Collection
1
1995
37
0.030
 Why?
Organoplatinum Compounds
3
1990
45
0.030
 Why?
Antidotes
1
1997
142
0.030
 Why?
Blood Component Transfusion
2
1994
84
0.030
 Why?
Animals, Newborn
1
2017
831
0.030
 Why?
Genetic Therapy
1
1997
297
0.030
 Why?
Digestive System
1
1995
28
0.030
 Why?
Transcriptional Activation
1
2017
371
0.030
 Why?
Vincristine
1
1995
114
0.030
 Why?
Mortality
1
1997
356
0.030
 Why?
Fertility
1
2016
160
0.030
 Why?
Interleukin-3
1
1994
25
0.030
 Why?
Hormones
1
2015
143
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2017
247
0.030
 Why?
Diagnosis, Differential
1
2019
1474
0.030
 Why?
Kidney
2
1995
1463
0.030
 Why?
Weight Gain
1
2018
535
0.030
 Why?
Pulmonary Fibrosis
3
1993
398
0.030
 Why?
Child, Preschool
6
2013
10969
0.030
 Why?
Bacterial Infections
1
1996
243
0.030
 Why?
Leukocyte Count
5
1996
322
0.030
 Why?
Tosyl Compounds
1
2014
14
0.030
 Why?
Odds Ratio
1
2017
1073
0.030
 Why?
Drug Discovery
1
2015
144
0.030
 Why?
Adipose Tissue
1
2018
644
0.030
 Why?
Hand-Foot Syndrome
1
2013
2
0.030
 Why?
Antioxidants
1
2017
589
0.030
 Why?
Protein Transport
1
2015
438
0.030
 Why?
Capecitabine
1
2013
45
0.030
 Why?
HEK293 Cells
1
2016
729
0.030
 Why?
Transplantation, Heterologous
1
2014
195
0.030
 Why?
Neoplasm Transplantation
1
2014
253
0.030
 Why?
Alternative Splicing
1
2015
225
0.030
 Why?
Necrosis
1
2014
240
0.030
 Why?
Erythropoietin
1
1994
94
0.030
 Why?
Cell Nucleus
1
2016
608
0.030
 Why?
Gene Silencing
1
2014
196
0.030
 Why?
Binding Sites
1
2016
1312
0.020
 Why?
Blood Cells
1
1993
39
0.020
 Why?
Cross-Sectional Studies
1
2024
5522
0.020
 Why?
Nutritional Status
1
2015
348
0.020
 Why?
CD24 Antigen
1
2012
20
0.020
 Why?
Recombinant Proteins
5
1997
1346
0.020
 Why?
Sensitivity and Specificity
2
2000
1911
0.020
 Why?
Anemia
1
1994
171
0.020
 Why?
Emergency Medical Services
1
2019
553
0.020
 Why?
Radionuclide Imaging
1
1992
114
0.020
 Why?
Diet, Reducing
1
2012
90
0.020
 Why?
Energy Intake
1
2015
501
0.020
 Why?
Psychotherapy, Group
1
2012
74
0.020
 Why?
Models, Biological
1
1999
1777
0.020
 Why?
Counseling
1
2015
390
0.020
 Why?
Antigens, CD34
3
1996
88
0.020
 Why?
Hyaluronan Receptors
1
2012
102
0.020
 Why?
Vascular Endothelial Growth Factor Receptor-1
1
2012
70
0.020
 Why?
Surveys and Questionnaires
1
2024
5802
0.020
 Why?
Feasibility Studies
4
1998
964
0.020
 Why?
Mice, SCID
1
2012
368
0.020
 Why?
Pandemics
1
2020
1634
0.020
 Why?
Tumor Burden
1
2012
308
0.020
 Why?
Fluorescent Antibody Technique
2
1990
381
0.020
 Why?
Logistic Models
1
2016
2071
0.020
 Why?
Biopsy, Needle
1
2011
188
0.020
 Why?
Mice, Inbred NOD
1
2012
596
0.020
 Why?
Disease Models, Animal
1
2021
4283
0.020
 Why?
Chromosomes, Human, Pair 9
1
1990
39
0.020
 Why?
Blast Crisis
1
1990
33
0.020
 Why?
Bilirubin
2
2002
88
0.020
 Why?
Colorado
1
2020
4515
0.020
 Why?
Chromosomes, Human, Pair 22
1
1990
45
0.020
 Why?
Immunoblotting
1
2010
304
0.020
 Why?
Pemetrexed
1
2010
33
0.020
 Why?
Glutamates
1
2010
58
0.020
 Why?
Health Status
1
2015
805
0.020
 Why?
Graft Survival
1
1993
523
0.020
 Why?
Antibodies, Anti-Idiotypic
1
1990
50
0.020
 Why?
Magnetics
1
1990
45
0.020
 Why?
Cytokines
1
1998
2072
0.020
 Why?
Gene Regulatory Networks
1
2012
309
0.020
 Why?
Urologic Diseases
1
1990
39
0.020
 Why?
Multiple Organ Failure
2
2002
122
0.020
 Why?
Kidney Diseases
2
1991
406
0.020
 Why?
Guanine
1
2010
81
0.020
 Why?
Real-Time Polymerase Chain Reaction
1
2010
348
0.020
 Why?
RNA, Messenger
1
2017
2797
0.020
 Why?
Microspheres
1
1990
135
0.020
 Why?
Health Behavior
1
2015
775
0.020
 Why?
Spinal Cord Neoplasms
1
1989
37
0.020
 Why?
Chromosome Aberrations
1
1990
157
0.020
 Why?
Blood
1
1990
107
0.020
 Why?
Cell Movement
1
2014
968
0.020
 Why?
Clone Cells
1
1990
265
0.020
 Why?
Promoter Regions, Genetic
1
2014
1237
0.020
 Why?
Pregnancy Trimester, Second
1
2009
79
0.020
 Why?
Central Nervous System Diseases
1
1990
68
0.020
 Why?
Hypertension
1
2018
1290
0.020
 Why?
Hematuria
1
1989
10
0.020
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
1990
121
0.020
 Why?
Vinblastine
2
2001
70
0.020
 Why?
Lymphoma
1
1990
209
0.020
 Why?
Creatinine
1
1991
485
0.020
 Why?
False Negative Reactions
1
1988
54
0.020
 Why?
Rats
1
2017
5541
0.020
 Why?
DNA Methylation
1
2014
642
0.020
 Why?
Pregnancy Trimester, First
1
2009
137
0.020
 Why?
Leukopenia
1
1988
30
0.020
 Why?
Niacinamide
1
2009
82
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
185
0.020
 Why?
Neurons
1
2017
1585
0.020
 Why?
Immunophenotyping
2
2000
323
0.020
 Why?
Histones
1
2014
636
0.020
 Why?
False Positive Reactions
1
1988
112
0.020
 Why?
Phenylurea Compounds
1
2009
97
0.020
 Why?
Hospitals, Veterans
1
2009
253
0.020
 Why?
Electrophoresis
1
1988
32
0.020
 Why?
Antigens, Differentiation
1
1988
83
0.020
 Why?
Transfection
1
2010
935
0.020
 Why?
Drug Interactions
1
1990
398
0.020
 Why?
Perilipin-1
1
2008
17
0.020
 Why?
Estrogen Receptor Modulators
1
2008
17
0.020
 Why?
Gene Expression Regulation
1
2017
2573
0.020
 Why?
Macrophages
2
1995
1548
0.020
 Why?
Exercise Therapy
1
2012
440
0.020
 Why?
Staining and Labeling
1
1988
153
0.020
 Why?
S100 Proteins
1
2008
37
0.020
 Why?
Antigens, Surface
1
1988
153
0.020
 Why?
Vimentin
1
1988
52
0.020
 Why?
Androstadienes
1
2008
77
0.020
 Why?
Community Health Services
1
2009
221
0.020
 Why?
Nervous System Diseases
1
1991
270
0.020
 Why?
Central Nervous System
1
1990
258
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2378
0.020
 Why?
Sarcoma, Kaposi
1
1988
81
0.020
 Why?
Lung Diseases
2
1992
766
0.020
 Why?
Bone Marrow Purging
2
1996
3
0.020
 Why?
Clinical Trials, Phase II as Topic
2
2000
70
0.020
 Why?
Biomarkers
1
2018
4095
0.020
 Why?
Academic Medical Centers
1
2009
506
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2015
1361
0.020
 Why?
Heart Diseases
1
1990
327
0.020
 Why?
Risk
2
2000
900
0.020
 Why?
Stem Cell Transplantation
1
2007
177
0.020
 Why?
Gastrointestinal Diseases
1
2008
207
0.020
 Why?
Phosphoproteins
1
2008
338
0.010
 Why?
Bevacizumab
1
2006
135
0.010
 Why?
Immunoglobulin G
1
1990
893
0.010
 Why?
Quality of Health Care
1
2009
642
0.010
 Why?
Melanoma
2
1988
759
0.010
 Why?
Body Mass Index
1
2012
2422
0.010
 Why?
Carrier Proteins
1
2008
735
0.010
 Why?
Ascites
1
2002
46
0.010
 Why?
Brain
1
2014
2703
0.010
 Why?
Phenotype
1
2010
3148
0.010
 Why?
Carcinoma, Lewis Lung
1
2001
17
0.010
 Why?
Carcinoma, Large Cell
1
2001
16
0.010
 Why?
Transplantation Conditioning
1
2002
173
0.010
 Why?
Hemorrhage
2
1998
716
0.010
 Why?
Phytohemagglutinins
1
2000
28
0.010
 Why?
CD4-CD8 Ratio
1
2000
22
0.010
 Why?
Hypersensitivity, Delayed
1
2000
28
0.010
 Why?
Lymphocyte Culture Test, Mixed
1
2000
52
0.010
 Why?
Drug Synergism
1
2001
371
0.010
 Why?
Microcomputers
1
2000
15
0.010
 Why?
Skin Tests
1
2000
96
0.010
 Why?
Graft vs Host Disease
1
2002
252
0.010
 Why?
Louisiana
1
2000
30
0.010
 Why?
Philadelphia
1
2000
51
0.010
 Why?
Immunoglobulins
1
2000
169
0.010
 Why?
Automation
1
2000
94
0.010
 Why?
Immunity
1
2000
142
0.010
 Why?
Personnel Selection
1
1980
78
0.010
 Why?
Lung
1
1992
4031
0.010
 Why?
Lipopolysaccharide Receptors
1
1999
85
0.010
 Why?
Heart Failure
1
1992
2038
0.010
 Why?
Marriage
1
1980
120
0.010
 Why?
Thalassemia
1
1998
7
0.010
 Why?
Interleukin-4
1
1999
214
0.010
 Why?
Receptors, Purinergic P1
1
1998
26
0.010
 Why?
Multicenter Studies as Topic
1
2000
305
0.010
 Why?
Microscopy, Fluorescence
1
2000
407
0.010
 Why?
Reference Values
1
2000
799
0.010
 Why?
Pilot Projects
2
1994
1728
0.010
 Why?
Acute Disease
1
2001
995
0.010
 Why?
Infant, Newborn
1
2009
6052
0.010
 Why?
Filgrastim
1
1997
10
0.010
 Why?
Adenoviruses, Human
1
1996
27
0.010
 Why?
Killer Cells, Natural
1
2000
450
0.010
 Why?
Heparin
1
1998
250
0.010
 Why?
Lymphoma, B-Cell
1
1998
109
0.010
 Why?
Tissue Plasminogen Activator
1
1998
223
0.010
 Why?
Pregnancy
1
2009
6725
0.010
 Why?
Freezing
1
1996
88
0.010
 Why?
Lymphocyte Activation
1
2000
1134
0.010
 Why?
Lymphocyte Depletion
1
1996
136
0.010
 Why?
Genes, Reporter
1
1996
271
0.010
 Why?
Carcinoma, Squamous Cell
1
2001
645
0.010
 Why?
Drug Tolerance
1
1995
103
0.010
 Why?
Reticulocyte Count
1
1994
6
0.010
 Why?
Kidney Function Tests
1
1995
156
0.010
 Why?
Topotecan
1
1994
13
0.010
 Why?
Incidence
1
2001
2801
0.010
 Why?
Liver
1
2002
1871
0.010
 Why?
Antigens, CD
1
1996
527
0.010
 Why?
Registries
1
2002
2038
0.010
 Why?
Urinary Bladder Diseases
1
1993
18
0.010
 Why?
Glioblastoma
1
1996
335
0.010
 Why?
Heart
1
1997
605
0.010
 Why?
Boston
1
1993
91
0.010
 Why?
Chromatography, High Pressure Liquid
1
1995
577
0.010
 Why?
Flow Cytometry
1
1996
1194
0.010
 Why?
Iron
1
1994
324
0.010
 Why?
Palliative Care
1
1998
818
0.010
 Why?
Cell Line
1
1996
2857
0.010
 Why?
Immunologic Factors
1
1993
237
0.010
 Why?
Cystitis
1
1990
21
0.010
 Why?
Metabolic Clearance Rate
1
1989
106
0.000
 Why?
Prostatic Neoplasms
1
1996
1024
0.000
 Why?
Introns
1
1990
256
0.000
 Why?
Platinum
1
1989
50
0.000
 Why?
Drug Combinations
1
1990
337
0.000
 Why?
Brain Diseases
1
1990
144
0.000
 Why?
Macrophage-1 Antigen
1
1988
28
0.000
 Why?
Bone Marrow Examination
1
1988
5
0.000
 Why?
Platelet Count
1
1988
86
0.000
 Why?
Erythrocyte Count
1
1988
20
0.000
 Why?
Methods
1
1988
63
0.000
 Why?
Pelvic Neoplasms
1
1988
26
0.000
 Why?
Erythroblasts
1
1988
20
0.000
 Why?
Infant
1
2002
9402
0.000
 Why?
DNA Damage
1
1990
420
0.000
 Why?
Acute Kidney Injury
1
1995
802
0.000
 Why?
Fever
1
1988
304
0.000
 Why?
In Vitro Techniques
1
1988
1085
0.000
 Why?
Pneumonia
1
1992
632
0.000
 Why?
Statistics as Topic
1
1987
296
0.000
 Why?
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (664) concept(s)
_
Co-Authors Expand Description
See all (59) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)